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AbstrAct
Introduction: The aim of this study was to use a 
validated acute rabbit model to test the toxicity 
of a novel formulation of fixed-combination 
travoprost 0.004%/timolol 0.5% ophthalmic 
solution, which contains the antimicrobial 
preservative polyquaternium-1 (PQ), compared 
with the commercial formulation of fixed 
combinations travoprost 0.004%/timolol 
0.5% ophthalmic solution and latanoprost 
0.005%/timolol 0.5% ophthalmic solution, 
which both contain the preservative 
benzalkonium chloride (BAK). Methods: Adult 
male New Zealand albino rabbits (n=24) were 
randomly divided into four groups. Phosphate-
buffered saline (PBS), travoprost/timolol PQ, 
travoprost/timolol BAK, or latanoprost/timolol 
BAK were instilled onto rabbit eyes one drop, 
15 times at 5 minute intervals. The ocular 
surface reactions were investigated at hour 4 
and day 1 using slit lamp examination; in-vivo 
confocal microscopy (IVCM) for cornea, limbus, 
and conjunctiva-associated lymphoid tissue 
(CALT); conjunctival impression cytology; and 
standard immunohistology in cryosections for 
detecting CD45+ infiltrating cells and MUC-
5AC-labeled cells. Results: Travoprost/timolol 
PQ was better tolerated than travoprost/timolol 
BAK or latanoprost/timolol BAK. This improved 
tolerance was evident via clinical observation 
under slit lamp, IVCM in different layers of the 
cornea and conjunctiva, conjunctival impression 
cytology of superficial epithelium aspects, 
and immunohistochemistry for inflammatory 
infiltration of CD45+ cells in the cornea and 
goblet cell distribution. Travoprost/timolol PQ 
was similar to PBS in regards to in-vivo findings, 
the Draize test for ocular irritation, and 
epithelial and limbal aspects as evaluated with 
IVCM. Treatment with either travoprost/timolol 
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PQ or PBS produced no obvious inflammatory 
infiltration inside and outside the CALT follicles, 
yielded similar IVCM toxicity scores and CD45+ 
cell counts, and eyes treated with either solution 
had normal goblet cells. Conclusion: The fixed 
combination of travoprost/timolol with 0.001% 
PQ had decreased ocular surface toxicity relative 
to the BAK-containing solutions. The potential 
benefit to the human ocular surface with once-
daily dosing needs to be evaluated clinically.
Keywords: benzalkonium chloride; Duotrav; 
in vivo; latanoprost; ocular surface toxicity; 
polyquad; timolol; travoprost; Xalacom
IntroductIon
Prostaglandins are the first-line monotherapy 
for lowering intraocular pressure (IOP) in 
patients with glaucoma and ocular hypertension 
because of their efficacy, favorable side effect 
profile, and once-daily administration. 
Nonetheless, many patients require multiple 
ophthalmic IOP-lowering medications in order 
to control their intraocular pressure. One 
study of 4444 newly diagnosed patients with 
glaucoma revealed that approximately 20% 
required adjunctive therapy, irrespective of the 
initial prostaglandin analog monotherapy.1 
Likewise a retrospective analysis found 
that approximately 20% of 12,202 patients 
with glaucoma treated with prostaglandin 
monotherapy required adjunctive therapy 
during the first year of treatment.2
Using more than one ophthalmic medication 
is difficult for many patients. Improper time 
adherence to the instillation of the second 
medication is common, and can be a safety 
issue.3 Even in a clinical trial where the timing 
of dosing is monitored, and where the patients 
are reminded of the dosing time electronically, 
patients have difficulty taking the medication at 
the appropriate time.3 Also, dosing errors related 
to underdosing or overdosing are more common 
in patients taking two ophthalmic medications.3
Instillation of several benzalkonium chloride 
(BAK)-preserved ophthalmic medications is 
another potential safety concern. Studies show 
that BAK is associated with decreased tear film 
stability, worsening of dry eyes, inflammatory 
cell infiltration, superficial punctate keratitis, 
blepharitis, and eyelid eczema.4-7 The BAK in 
eye drops can cause or worsen ocular surface 
disease, and patients with glaucoma taking 
several BAK-containing drops have a higher 
risk of developing ocular surface disease.8,9 
Reportedly, 48%-59% of patients with glaucoma 
or ocular hypertension have symptoms of ocular 
surface disease in at least one eye.8,9 Use of fixed-
combination products can reduce many of these 
safety concerns.
Even though topical  ocular  f ixed 
combinations reduce the exposure to the 
antimicrobial preservatives, all currently available 
prostaglandin-analog fixed combinations 
contain BAK. For example, travoprost 0.004%/
timolol 0.5% ophthalmic solution (travoprost/
timolol BAK, DuoTrav®; Alcon Laboratories, Inc., 
Fort Worth, TX, USA) contains 0.015% BAK, and 
latanoprost 0.005%/timolol 0.5% ophthalmic 
solution (latanoprost/timolol BAK, Xalacom®; 
Pfizer, New York, NY, USA) contains 0.02% 
BAK. Additional benefits may result if products 
contain a less toxic antimicrobial preservative. 
To this end, travoprost/timolol BAK has been 
reformulated, and BAK has been replaced 
with the polymeric quaternary ammonium 
antimicrobial preservative polyquaternium-1 
(PQ; Polyquad®; Alcon Laboratories UK, Ltd., 
Hemel Hempstead, Hertfordshire, UK). PQ 
has been successfully used in contact lens 
solutions, artificial tear substitutes, and an 
ocular hypertensive medication.10-12 According 
to ophthalmic research in animal models, PQ 
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is safer for the ocular surface than BAK.10,13,14 In 
rabbits, PQ produced less corneal staining than 
BAK, and produced only superficial epithelial 
damage.14 Even at high doses, PQ was much less 
toxic than BAK in an acute rat model with slit-
lamp examination, fluorescein, and red phenol 
tests, impression cytology collection, and corneal 
in-vivo confocal microscopy (IVCM) analyses.10
The purpose of this study was to assess the 
toxicological profile of travoprost/timolol 
preserved with PQ versus travoprost/timolol BAK, 
and latanoprost/timolol BAK in a validated acute 
rabbit model.15 A set of new experimental tools, 
such as corneal IVCM, conjunctival impression 
cytology (CIC), and immunohistology, 
were used.
Methods
Male albino New Zealand rabbits (CEGAV 
S.S.C.; Saint-Mars-d’Egrenne, France) weighing 
approximately 2.5 kg were anesthetized with a 
mixture of ketamine (35 mg/kg; Imalgène® 500; 
Merial, Lyon, France), and xylazine (5 mg/kg; 
Rompun®; Bayer, Puteaux, France). After the 
animals were anesthetized and before all 
experiments, the ocular surface integrity was 
examined by slit lamp microscopy. Twenty-
four rabbits were randomly divided into 
four groups. Each group was composed of 
12 eyes of six rabbits: six eyes for assessments 
4 hours after treatment (H4), and six eyes for 
assessments 1 day after treatment (D1). All 
rabbits were used for clinical observations, 
IVCM observations, and CIC, and were later 
killed for immunohistological procedures. 
Data were interpreted and scored in a blind 
manner. All experiments were conducted in 
accordance with the Association for Research in 
Vision and Ophthalmology’s (ARVO) Statement 
for the Use of Animals in Ophthalmic and 
Vision Research.
Four sterile compounds were evaluated: 
(1) phosphate-buffered saline (PBS; Eurobio, 
Les Ulis, France); (2) travoprost/timolol PQ, 
preserved with PQ 0.001% (Alcon Laboratories); 
(3) travoprost/timolol BAK, preserved with 
0.015% BAK; (4) latanoprost/timolol BAK, 
preserved with 0.02% BAK. Sterile pipette tips 
were used to instill 50 µl drops, 15 times at 
5 minute intervals to the rabbit eyes. The first 
instillation was considered time zero.
In-Vivo Findings and Draize test
Using slit lamp microscopy, the eyes were 
examined at H4 and D1 for ocular irritation, and 
scored according to a weighted scale for grading 
the severity of ocular lesions. The scale was 
modified from the Draize test, as used in previous 
studies.16-18 Briefly, the degree of hyperemia, 
swelling of the conjunctiva (chemosis) and 
tearing, areas of cornea opacity, increased 
prominence of folds, and congestion of the 
iris were evaluated, with a possible maximum 
combined score of 110. Corneal opacity and the 
increased prominence of folds and congestion of 
the iris were always negative (score = 0). The only 
variables with positive observations (chemosis, 
tearing, and redness) are presented in the results 
section. Chemosis was rated 0 to 3, with 0 = 
no chemosis and 3 = obvious chemosis with 
more than half of the eyelid closed. Tearing was 
rated 0 to 3, with 0 = no tearing and 3 = tearing 
covering the entire eyeball. Redness was rated 0 
to 3, with 0 = normal blood vessels and 3 = 
diffuse beefy red. Thus the maximum possible 
score for the positive observations was 9.
IVCM Observation and IVCM-Conjunctiva-
Associated Lymphoid Tissues Scale
As in previous animal studies, the laser scanning 
IVCM Heidelberg retina tomograph (HRT) II/
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Rostock cornea module (Heidelberg Engineering 
GmbH, Heidelberg, Germany) was used to 
examine the entire ocular surface.10,16-18 For all 
eyes, at least 10 confocal microscopic images 
of each layer in the conjunctiva-associated 
lymphoid tissues (CALT)/limbus/cornea were 
analyzed. The final scores were the averages of 
both eyes of three animals (n=6). In order to 
quantify the observed patterns, the IVCM-CALT 
scale was used to quantify the whole ocular 
surface toxicity as shown in Table 1.
CIC Collection
CIC specimens were collected by techniques 
previously described.18,19 Brief ly,  two 
nitrocellulose membrane filters (Millipore 
Corporation, Bedford, MA, USA) were applied 
Table 1. In-vivo confocal microscopy (IVCM) scoring for evaluating ocular toxicity.
Tissue 
Ocular surface damage IVCM 
score*Property Toxicity observed
Superficial epithelium 
(max 10 points) 
Desquamation Partial 2
Total important 4
Shape/size Anisocytosis, microcytosis, macrocytosis, irregular shape, 
edematous cells, swollen cells, loss of cell borders
 
2
Reflectivity Abnormal reflectivity patterns: hyper-reflective cells, 
nuclei visible in hyper-reflective cells or not
 
2
Inflammation Presence of inflammatory infiltration 2
Basal epithelium  
(max 10 points)
Disorganization N/A 2




Anterior stroma  
(max 10 points)
Disorganization N/A 2




Limbus and conjunctiva  
(max 10 points)
Presence of capillary bud 








Presence of inflammatory 






CALT inside + outside 
the follicle  
(max 8 points)





CALT=conjunctiva-associated lymphoid tissues; N/A=not applicable.
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onto the superior bulbar conjunctiva and 
then dipped into tubes containing 1.5 mL 
cold PBS with 4% paraformaldehyde (4% PFA). 
The membranes were then washed in distilled 
water, dehydrated in ethanol, stained with cresyl 
violet solution (1%, # 5235, Merck, Fontenay-
sous-Bois, France) for 30 minutes, air-dried, and 
mounted in Eukitt medium (CML, Nemours 
Cedex, France). The CIC specimens were 
photographed with a Leica® DM5000 fluorescent 
microscope (Leica Microsystems, Wetzlar, 
Germany), and all the images were taken using 
magnification of ×200.
The morphology of the CIC specimen 
was scored according to a modified Nelson 
classification, thereby assigning grades to the 
ocular surface.20 Morphological parameters such as 
epithelial cell changes, inflammatory infiltration, 
and density of goblet cells were scored 0 to 3, with 
0 = normal/none and 3 = abundant/massive. The 
maximum score was 30.
Cryosections and Immunohistology
Two rabbits in each group were euthanized 
with a lethal dose of pentobarbital at selected 
time points. Enucleated eyes were fixed in 4% 
PFA and embedded in OCT Embedding Matrix 
(CellPath Ltd., Newtown, UK). The 10 µm cryo- 
sections were incubated with mouse antibodies 
directed against rabbit CD45 (1:50; CBL1412; 
Cymbus Biotechnology, Chandlers Ford, UK) to 
detect inflammatory cell infiltration, or directed 
against MUC-5AC (donated by Jacques Bara, 
INSERM, University Paris 6, Paris, France) to 
detect goblet cells. Sections were stained with 
secondary antibody (488 goat anti-mouse; Alexa 
Fluor®; Molecular Probes; Eugene, OR, USA) and 
propidium iodide.
Images were digitized using a Leica DM5000 
fluorescent microscope equipped with a 
digital camera and image analysis software. 
Immunohistological data from two different 
rabbit eyes in three or more different areas, and 
from a length of 500 µm of cornea or conjunctiva 
(= one field for counting), were analyzed in a 
masked fashion.
Statistical Analysis
Results are expressed as mean ± standard error 
(SEM). The groups were compared using two-
way analysis of variance (ANOVA) followed by 
multiple pair-wise comparisons using Fisher’s 
method adjustment (Statview Version 5; SAS 
Institute Inc., Cary, NC, USA).
results
In-Vivo Findings
Eyes treated with PBS (Figure 1A) had no obvious 
irritation on the ocular surface. Travoprost/
Figure 1. Microphotographs of typical clinical features at 
hour 4 (H4). (A) Phosphate buffered saline (PBS) induced 
no hyperemia, chemosis, or secretions on the conjunctiva. 
(B) Travoprost/timolol polyquarternium (PQ) induced 
very slight redness with no chemosis or secretions on the 
conjunctiva. (C) Travoprost/timolol benzalkonium chloride 
(BAK) induced conjunctival hyperemia with mild chemosis. 
(D) Latanoprost/timolol BAK induced diffuse hyperemia 
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timolol PQ (Figure 1B) was also well tolerated, 
producing very slight redness without tearing, 
chemosis, or secretions. Travoprost/timolol BAK 
(Figure 1C) induced conjunctival hyperemia 
with slight chemosis. In contrast to Figure 1B, 
latanoprost/timolol BAK (Figure 1D) induced 
obvious diffuse hyperemia, tearing, and 
chemosis on the conjunctiva at H4 (4 hours 
after the first instillation or 2.75 hours after the 
last instillation).
Draize Test
At H4, the Draize test revealed that travoprost/
timolol PQ produced significantly less ocular 
irritation than travoprost/timolol BAK (P<0.02) 
and latanoprost/timolol BAK (P<0.02; Figure 2). 
Travoprost/timolol PQ induced a low Draize test 
score, which did not differ significantly from the 
PBS score. Travoprost/timolol BAK presented a 
moderately elevated Draize score, which was 
significantly less than latanoprost/timolol BAK 
(P<0.02), but significantly greater than PBS 
(P<0.01), and travoprost/timolol PQ (P<0.02).
At D1 (24 hours after the first instillation 
or 22.75 hours after the last instillation), the 
Draize scores decreased for all treatment groups. 
There were no significant differences between 
the treatments at D1 for the Draize measure of 
ocular irritation (Figure 2).
IVCM and IVCM-CALT Scale
Surface Epithelium
At H4, PBS-instilled (Figure 3A) rabbit eyes 
presented a surface epithelium with a regular 
mosaic appearance and brightly reflective nuclei. 
The eyes instilled with travoprost/timolol PQ 
(Figure 3B) had epithelial aspects that were 
similar to PBS-instilled eyes, with no important 
desquamation, normal cell shape and size, 
and no inflammatory infiltration. Travoprost/
timolol BAK (Figure 3C) induced moderate 
damage to the surface epithelium; showing 
partial desquamation, abnormal reflectivity 
patterns, and anisocytosis with irregular cell 
shape. Inflammatory cells were also occasionally 
observed. After instillations of latanoprost/
timolol BAK (Figure 3D), there was evidence 
of desquamation of the surface epithelium, 
and the remaining epithelial cells presented 
swelling, irregular cell shape, and anisocytosis 
aspects. Also, there was marked hyper-reflective 
inflammatory cell infiltration after instillation of 
latanoprost/timolol BAK.
At D1, the outcomes were similar to 
that at H4. PBS and travoprost/timolol PQ 
(Figure 4A-B) presented similar normal aspects 
of the surface epithelium. The travoprost/
timolol BAK (Figure 4C) and latanoprost/
timolol BAK (Figure 4D) groups again presented 
Figure 2. Modified Draize test scores to evaluate ocular 
irritation (mean±standard error [SEM]) at hour 4 (H4) 
and day 1 (D1) in rabbit eyes (n=6 eyes/time point); 
*P<0.01 vs. phosphate buffered saline (PBS); †P<0.02 vs. 
travoprost/timolol polyquarternium (PQ); ‡P<0.02 vs. 
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abnormalities, with partial desquamation, and 
hyper-reflectivity of the epithelium. However, 
in the latanoprost/timolol BAK and the 
travoprost/timolol BAK groups the inflammatory 
infiltration decreased (but not to normal levels) 
compared with H4, and inflammatory cells were 
occasionally observed.
Basal Epithelium
At H4, PBS (Figure 3A) and travoprost/timolol 
PQ (Figure 3B) both induced minimal levels 
(<5 cells/mm2) of inflammatory cell infiltrates 
in the basal epithelium. Travoprost/timolol 
BAK (Figure 3C) induced a moderate level 
of bright hyper-reflective inflammatory 
infiltrates (62.3±7.3 cells/mm2). Latanoprost/
timolol BAK (Figure 3D) induced the greatest 
amount of inflammatory cell infiltration 
(135.4±16.1 cells/mm2). As shown in Figure 4, 
the findings at D1 were similar to H4.
Limbus
At H4 and D1, normal limbal aspects were 
observed after the instillations of PBS, travoprost/
timolol PQ, and travoprost/timolol BAK 
(Figures 3A-C and 4A-C). Obvious inflammatory 
Figure 3. At hour 4 (H4) the corneal in-vivo confocal microscopy (IVCM) images of the rabbit corneal superficial 
epithelium (line 1), basal epithelium (line 2), limbus (line 3), and conjunctiva-associated lymphoid tissue (CALT) (line 4) 
after the applications of (A) phosphate-buffered saline (PBS), (B) travoprost/timolol polyquarternium (PQ), (C) travoprost/
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infiltrations in the peripheral cornea and 
limbus area were found after instillation of 
latanoprost/timolol BAK (Figure 3D). This 
infiltration persisted at D1 (Figure 4D), but at a 
decreased level.
CALT
At H4, after instillation of PBS or travoprost/
timolol PQ, the CALT follicles were inactive, 
without any obvious inflammatory infiltration 
inside and outside of the follicle (Figure 3A-B). 
In contrast, following instillation of travoprost/
timolol BAK or latanoprost/timolol BAK, obvious 
increases of high levels of inflammatory cell 
infiltration were observed especially outside 
the CALT follicle (Figure 3C-D). At D1, the 
inflammatory cell infiltration decreased but 
persisted for both the travoprost/timolol BAK and 
latanoprost/timolol BAK groups (Figure 4C-D).
IVCM Scale Score
An IVCM scale score was used to quantify the 
cytotoxic reactions according to the degree of 
ocular surface damage (Figure 5). At H4 and D1, PBS 
and travoprost/timolol PQ instillations produced 
Figure 4. At day 1 (D1) the corneal in-vivo confocal microscopy (IVCM) images of the rabbit corneal epithelium 
(line 1), basal epithelium (line 2), limbus (line 3), and conjunctiva-associated lymphoid tissue (CALT) (line 4) after the 
applications of (A) phosphate-buffered saline (PBS), (B) travoprost/timolol polyquarternium (PQ), (C) travoprost/timolol 
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low IVCM toxicity scores, and there was no 
significant difference between them. Travoprost/
timolol PQ produced significantly lower total 
ocular toxicity scores than latanoprost/timolol 
BAK (P<0.0003 at H4 and D1) and travoprost/
timolol BAK (P=0.044 at H4, and P=0.012 at D1). 
Compared with the other treatments, travoprost/
timolol BAK presented a moderately high IVCM 
score, which was significantly less than the 
latanoprost/timolol BAK score (P<0.02 at H4 
and D1), but significantly greater than the scores 
produced by PBS (P=0.044 at H4, and P=0.012 at 
D1) and travoprost/timolol PQ (P=0.044 at H4, 
and P=0.012 at D1).
Impression Cytology Staining
At H4, eyes instilled with PBS had normal, 
polyhedral conjunctival epithelium with 
goblet cells (Figure 6A). The eyes instilled 
with travoprost/timolol PQ presented a 
homogeneous, slightly metaplastic epithelium 
with normal goblet cells (Figure 6B). Eyes 
instilled with travoprost/timolol BAK (Figure 6C) 
or latanoprost/timolol BAK (Figure 6D) were 
infiltrated with numerous inflammatory cells, 
principally consisting of polynuclear cells, 
and also lymphocytes. Further, the impression 
cytology showed that the conjunctival epithelial 
Figure 5. In-vivo confocal microscopy (IVCM) scores 
(mean±standard error [SEM]) for total ocular surface 
toxicity at hour 4 (H4) and day 1 (D1) in rabbit eyes (n=6 
eyes/time point). Refer to Table 1 for scoring. *Statistically 
significant vs. phosphate-buffered saline (PBS) (travoprost/
timolol benzalkonium chloride [BAK]): H4, P=0.044; D1, 
P=0.012; latanoprost/timolol BAK: H4, P<0.0001 and 
D1, P=0.0001). †Statistically significant vs. travoprost/
timolol polyquarternium (PQ ) (travoprost/timolol BAK: 
H4, P=0.028; D1, P=0.037; latanoprost/timolol BAK: 






























































Figure 6. Superficial conjunctival cell changes at hour 4 
(H4) after repeated instillations of eye drops, as measured 
with impression cytology staining with cresyl violet. Images 
taken with an objective lens ×20. (A) Phosphate-buffered 
saline (PBS): clearly visible goblet cells; (B) travoprost/
timolol polyquarternium (PQ): homogeneous, slightly 
metaplastic epithelium with normal goblet cells; 
(C) travoprost/timolol benzalkonium chloride (BAK): 
numerous inflammatory cells, conjunctival epithelial 
cells with abnormal desquamation, swelling, and 
anisocytosis; and (D) latanoprost/timolol BAK: numerous 
inflammatory cells, conjunctival epithelial cells with 
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cells of eyes exposed to travoprost/timolol BAK 
or latanoprost/timolol BAK were dramatically 
damaged with abnormal desquamation, swelling, 
and anisocytosis.
At D1, eyes instilled with PBS (Figure 7A) 
or travoprost/timolol PQ (Figure 7B) presented 
a normal conjunctival epithelium with visible 
goblet cells. The eyes instilled with travoprost/
timolol BAK (Figure 7C) or latanoprost/
timolol BAK (Figure 7D) had decreased levels 
of inflammatory infiltrations compared with 
H4. In some imprints of eyes instilled with 
latanoprost/timolol BAK, islets of lymphocytes 
remained among the conjunctival epithelium 
(Figure 7D).
Figure 8 shows the modified Nelson’s 
scores, which were used to quantify the 
Figure 7. Superficial conjunctival cell changes at day 1 
(D1) after repeated instillations of eye drops, as measured 
with impression cytology staining with cresyl violet. Images 
taken with an objective lens ×20. (A) Phosphate-buffered 
saline (PBS): normal epithelium, visible goblet cells; 
(B) travoprost/timolol polyquarternium (PQ): normal 
epithelium, visible goblet cells; (C) travoprost/timolol 
benzalkonium chloride (BAK): inflammatory infiltration; 












image information, including conjunctival 
epithelium aspects, goblet cell presentation, 
and inflammatory infiltration level. At H4 
and D1, eyes treated with PBS or travoprost/
timolol PQ had low Nelson scores, which were 
not significantly different from each other. At 
H4, latanoprost/timolol BAK (P<0.0005) and 
travoprost/timolol BAK (P<0.02) had significantly 
higher Nelson scores than PBS or travoprost/
timolol PQ, which is attributed to the associated 
inflammatory infiltration and conjunctival 
epithelium damage. At D1, the inflammatory 
infiltration associated with latanoprost/timolol 
BAK and travoprost/timolol BAK decreased. 
Accordingly, there were no significant differences 
between the four treatment groups (Figure 8).
Figure 8. Conjunctival impression cytology scores (Nelson 
scoring, mean ± standard error [SEM]), evaluating 
epithelium aspects, goblet cells, and inflammatory 
infiltration level, at hour 4 (H4) and day 1 (D1) in rabbit 
eyes (n=6 eyes/time point). *Statistically significant vs. 
phosphate-buffered saline (PBS ) (travoprost/timolol 
benzalkonium chloride [BAK]: P<0.02, latanoprost/
timolol BAK: P<0.0005 at H4). †Statistically significant 
vs. travoprost/timolol polyquarternium (PQ) (travoprost/





























































Adv Ther (2011)  28(4):311-325. 321
Immunostaining of CD45+
Immunostaining of CD45+ inflammatory 
cells in the cornea are shown in Figure 9A-D, 
and the immunopositive cell counts are 
presented in Figure 9E. At H4, eyes instilled 
with PBS had few CD45+ inflammatory 
cells (Figure 9A, mean: 0.83 cells/field). 
Travoprost/timolol PQ induced only two 
cells/field, which was not significantly 
different from PBS. However, travoprost/
t imolo l  BAK induced 9 .8 ce l l s / f i e ld 
and latanoprost/t imolol  BAK induced 
14.5 cells/field, which was significantly more 
CD45+ cells than induced by PBS (P<0.0001 
for  both)  and travoprost/t imolol  PQ 
(P<0.0001 for both). Travoprost/timolol BAK 
also induced significantly fewer CD45+ cells 
than latanoprost/timolol BAK (P<0.0006).
At D1, both PBS and travoprost/timolol PQ 
induced less than two cells/field; there was 
no significant difference between the groups. 
Travoprost/timolol BAK and latanoprost/
timolol BAK continued to have moderate levels 
of CD45+ cells in the cornea (for travoprost/
timolol BAK, P=0.0002 when compared with PBS 
and P<0.0001 when compared with travoprost/
timolol PQ groups; for latanoprost/timolol 
















































































Figure 9. Immunostaining of CD45+ cells (green) in cornea cryosections (images taken with an objective lens ×10) at 
hour 4 (H4). (A) Phosphate-buffered saline (PBS): few CD45+ cells; (B) travoprost/timolol polyquarternium (PQ): few 
CD45+ cells; (C) travoprost/timolol benzalkonium chloride (BAK): moderate amount of CD45+ cells; (D) latanoprost/
timolol BAK: large amount of CD45+ cells; (E) CD45+ inflammatory cell counts (mean ± standard deviation [SEM]) 
in cornea at H4 and day 1 (D1) (n=6 eyes/time point). *Statistically significant vs. PBS (travoprost/timolol BAK: H4, 
P<0.0001; D1, P=0.0002; latanoprost/timolol BAK: H4 and D1, P<0.0001). †Statistically significant vs. travoprost/
timolol PQ (travoprost/timolol BAK: H4 and D1, P<0.0001; latanoprost/timolol BAK: H4 and D1, P<0.0001). ‡H4, 
P=0.0006 vs. travoprost/timolol BAK.
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Immunostaining of MUC-5AC+
Immunostaining against MUC-5AC+ goblet cells 
in rabbit cryosections is shown in Figure 10A-
D, and cell counts are presented in Figure 10E. 
The normal goblet cells appear as green, round 
patterns with a homogeneous distribution. At 
H4, PBS instillation clearly maintained normal 
aspects and distribution of goblet cells in the 
superficial layer of conjunctiva, with a mean 
of 8.17 cells/field. Travoprost/timolol PQ had 
a mean of 9.83 cells/field, which was not 
significantly different from PBS. For travoprost/
timolol BAK and latanoprost/timolol BAK, 
obvious decreases of goblet cell number and 
goblet cell size were found with respective mean 
counts of 4.5 cells/field and 4.33 cells/field 
(respectively P<0.006 and P<0.007 vs. PBS 
and P<0.0003 and P<0.0004 vs. travoprost/
timolol PQ).
The goblet cell findings at D1 were similar 
to H4. Eyes instilled with PBS or travoprost/
timolol PQ presented with normal goblet cell 
counts: 8.67 cells/field and 10.33 cells/field, 
respectively. Travoprost/timolol BAK and 
latanoprost/timolol BAK instillation clearly 
damaged the goblet cells. There was a 
significant decrease in goblet cell counts with 
travoprost/timolol BAK-instilled eyes having 
4.83 cells/field (P<0.02 vs. PBS and P<0.0008 vs. 
travoprost/timolol PQ) and latanoprost/timolol 
BAK-instilled eyes having 4.13 cells/field 
(P<0.003 vs. PBS and P<0.0001 vs. travoprost/
timolol PQ).
Figure 10. Immunostaining of MUC-5AC+ mucocyte cells (green) in conjunctiva cryosections (images taken with an 
objective lens ×10) at hour 4 (H4). (A) Phosphate-buffered saline (PBS): normal distribution of goblet cells; (B) travoprost/
timolol polyquarternium (PQ): normal, homogeneous distribution of goblet cells; (C) travoprost/timolol benzalkonium 
chloride (BAK): decreased goblet cell density; (D) latanoprost/timolol BAK: decreased goblet cell density; (E) MUC-
5AC+ mucocytes in the conjunctiva at H4 and day 1 (D1) (n=6 eyes/time point). *Statistically significant vs. PBS 
(travoprost/timolol BAK: H4, P<0.006; D1, P<0.02; latanoprost/timolol BAK: H4, P<0.007 and D1, P<0.003). 
†Statistically significant vs. travoprost/timolol PQ (travoprost/timolol BAK: H4, P<0.0003; D1, P<0.0008; latanoprost/
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dIscussIon
The aim of this in-vivo, repeated dosing, 
acute instillation model was to distinguish 
the ocular surface toxicity level of different 
eye drops. The dosing does not mimic real 
life and would be considered overdosing 
in humans; however, it is a good model to 
evaluate toxicity. After instilling the drops 
15 times in rabbits, the newly developed 
travoprost/timolol PQ was better tolerated 
than the commercially available travoprost/
timolol BAK and latanoprost/timolol BAK. 
This improved tolerance was evident not 
only via clinical observation under slit 
lamp, but also by IVCM in the different 
layers of the cornea and conjunctiva, by 
CIC for superficial epithelium aspects, and 
by immunohistochemistry for inflammatory 
infiltration of CD45+ cells in the cornea and 
goblet cell distribution. Indeed, instillation 
of travoprost/timolol PQ was similar to 
instillation of PBS in regards to the in-vivo 
findings, the Draize test for ocular irritation, 
and epithelial and limbal aspects as evaluated 
with IVCM. Furthermore, instillation with 
either travoprost/timolol PQ or PBS produced 
no obvious inflammatory infiltration inside 
and outside the CALT follicles, yielded similar 
IVCM toxicity scores and CD45+ cell counts, 
and eyes treated with either solution had 
normal goblet cell presentation.
The findings from this in-vivo study 
support the results of earlier in-vitro studies. 
One in-vitro study compared the cytotoxicity 
of travoprost/timolol PQ, travoprost/
timolol BAK, and latanoprost/timolol BAK 
in several assays of cell viability, apoptosis, 
and oxidative stress.21 Cultured human 
conjunctival epithelial cells incubated with 
travoprost/timolol PQ had significantly better 
cell viability and significantly less evidence 
of apoptosis than cells incubated with 
travoprost/timolol BAK or latanoprost/timolol 
BAK.21 Also, travoprost/timolol PQ produced 
significantly less induction of oxidative stress 
than latanoprost/timolol BAK.21 Similarly, in 
another in-vitro study, exposure to travoprost 
ophthalmic solution preserved with BAK 
yielded statistically more live epithelial and 
corneal cells in culture than cells exposed 
to BAK alone.22 Also, travoprost ophthalmic 
solution preserved with PQ was statistically 
less toxic to corneal and conjunctival cells in 
culture than travoprost ophthalmic solution 
preserved with BAK.22 Similarly, in the present 
study travoprost/timolol PQ produced a 
significantly lower total ocular toxicity score 
than travoprost/timolol BAK and latanoprost/
timolol BAK in vivo. Also, travoprost/timolol 
BAK and latanoprost/timolol BAK induced 
damage to the surface epithelium; showing 
partial desquamation, abnormal reflectivity 
patterns, and anisocytosis with irregular cell 
shape. In contrast, rabbit eyes treated with 
travoprost/timolol PQ were similar to PBS and 
the cells of the surface epithelium were of 
normal shape and size.
A limitation of this study is that the drugs 
were not compared with their respective 
antimicrobial preservatives. In a previous 
study with the same experimental design 
BAK 0.015% and PQ 0.001% control groups were 
included.13 The study revealed that rabbit eyes 
treated with PQ 0.001% had no obvious ocular 
surface irritation or changes in microstructures 
of the whole ocular surface, no inflammatory 
infiltration, or cell damage as measured by 
impression cytology, no altered levels of 
goblet cell counts, and few CD45+ cells in the 
cornea.13 In contrast, rabbit eyes treated with 
BAK 0.015% induced diffuse hyperemia and 
chemosis on the conjunctiva, abnormal changes 
in the ocular surface microstructure, significant 
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ocular surface toxicity, epithelial cell damage, 
inflammatory cell infiltration, decreased goblet 
cell density, and significantly more CD45+ cells 
in the cornea than PQ 0.001%.13
conclusIon
The in-vivo and in-vitro analyses of the novel 
formulation of travoprost/timolol PQ indicate 
that replacing BAK with PQ has the potential 
to produce clinically beneficial outcomes. The 
benefit to the human ocular surface needs to 
be evaluated clinically. However, it is obvious 
that compared with concomitant dosing, fixed 
combinations of ophthalmic medications 
decrease the exposure to the toxic preservative 
BAK, and the fixed combination of travoprost/
timolol PQ with 0.001% PQ could further 
decrease the cytotoxicity and risk of ocular 
surface disease by eliminating ocular exposure to 
BAK. Clinical studies are needed to confirm these 
findings in patients with ocular hypertension or 
open-angle glaucoma.
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